CHA Biotech subsidiary CHAMEDITECH announced on the 19th that it will introduce 'Seltermi Revive HS,' which alleviates hair loss. This product can be used on the scalp and hair in hospitals and clinics. It supplies oxygen and nutrients to hair follicles to aid hair growth.
The Ministry of Food and Drug Safety announced on the 19th that it has signed a business agreement with the Army Headquarters to create a drug-free military culture. The initiative aims to share the seriousness of drug addiction among those in their 20s and conduct prevention education and rehabilitation projects. According to the Ministry, the share of drug offenders in their 20s rose from 21.9% in 2019 to 32.6% last year.
GeoYoung announced on the 19th that it will pilot the delivery of pharmaceuticals using electric vehicles in collaboration with Kia. GeoYoung will deliver pharmaceuticals from over 50 logistics hubs nationwide. The company plans to demonstrate the use of Kia's PV5 on certain routes while reducing carbon emissions.
Hallym University Sacred Heart Hospital announced on the 19th that Professor Lee Jung-woo of the Department of Surgery has surpassed 300 cases of minimally invasive pancreaticoduodenectomy using laparoscopy and the Da Vinci robot. This challenging surgery involves resecting and reconstructing multiple organs, such as the head of the pancreas, duodenum, bile duct, and gallbladder, at once. Eighty percent of the surgeries performed by the professor were on high-risk patients with malignant tumors. He conducted the surgeries safely and meticulously.
Seoul National University Hospital announced on the 19th that it received a donation of 2 billion won from Samchuly Group. The hospital created the Samchuly Group Robotic Surgery Training Center. It plans to train and research robotic surgery for residents both domestically and internationally. The donation was made by Samchuly Group to mark its 70th anniversary.
GI Innovation announced on the 19th that the patent registration for its metabolic immune anticancer drug 'GI-108' has been confirmed in the United States. GI-108 effectively guides the attack on cancer cells. It is currently conducting Phase 1 and 2a clinical trials targeting patients with non-small cell lung cancer and kidney cancer.
Biosolution announced on the 19th that it has finalized clinical trials for its candidate substance 'VVZ-3416,' a treatment for degenerative central nervous system diseases. VVZ-3416 inhibits the progression of degenerative central nervous system diseases and prevents side effects. It also presents the possibility of fundamental treatment. The goal is to start domestic Phase 1 trials in the second half of next year.
Health management corporation iCoop announced on the 19th that it will introduce 'DoctorVice 2.0.' DoctorVice is a primary chronic disease management platform. It has expanded its target management to encompass a range of medical departments from diabetes and hypertension. The platform provides educational information tailored to the characteristics of each department and manages patients according to their responses. This version will be presented under the name of Smart Education Service (SES).